Skip to main content
Fig. 3 | Renal Replacement Therapy

Fig. 3

From: Efficacy and safety of plasma hemodiafiltration (PHDF) in pediatric patients with multiple organ dysfunction syndrome with shock and DIC: a preliminary study

Fig. 3

Changes in vital sign markers during plasma hemodiafiltration. a MAP. b HR. c CVP. Both MAP and CVP increased, and HR showed a downward trend until near the 4th hour of treatment, after which MAP and CVP showed a moderate downward trend. Data are expressed as a ratio to the value before starting plasma hemodiafiltration. MAP, mean arterial pressure; HR, heart rate; CVP, central venous pressure. *p < 0.05 compared with before the treatment by Kruskal–Wallis test and post hoc Steel tests

Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us